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 8 
Abstract 9 
Cancer is now considered a multifactorial disorder with different aetiologies and outcomes. Yet, all cancers share 10 
some common molecular features. Among these, the reprogramming of cellular metabolism has emerged as a 11 
key player in tumour initiation and progression. The finding that metabolic enzymes such as fumarate hydratase 12 
(FH), succinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), when mutated, cause cancer 13 
suggested that metabolic dysregulation is not only a consequence of oncogenic transformation, but that it can act 14 
as cancer driver. However, the mechanisms underpinning the link between metabolic dysregulation and cancer 15 
remain only partially understood. In this review we discuss the role of FH loss in tumorigenesis, focusing on the 16 
role of fumarate as a key activator of a variety of oncogenic cascades. We also discuss how these alterations are 17 
integrated and converge towards common biological processes. This review highlights the complexity of the 18 
signals elicited by FH loss, describes that fumarate can act as a bona fide oncogenic event, and provides a 19 
compelling hypothesis of the step wise neoplastic progression after FH loss. 20 
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1. Introduction 47 
Oncogenesis is a multistep process during which cells acquire molecular features known as “Hallmarks of 48 
Cancer”, which pave the way to malignant transformation [1]. The reprogramming of cellular metabolism is now 49 
widely considered a pivotal hallmark of cancer that allows cancer cells to survive, proliferate, and 50 
metastasize[2]. Although added to the list of the hallmarks only recently [2], a first piece of evidence that 51 
cellular metabolism is reprogrammed in cancer was provided already in 1887 by Ernst Freund, a Viennese 52 
physicians, who observed high sugar levels in the blood of cancer patients [3]. Based on this observation he 53 
proposed that reducing the amount of sugar could impact the tumour growth [3]. In 1911 the German scientist 54 
Wassermann postulated that accelerated proliferation of cancer cells was associated with an increased oxygen 55 
consumption [4]. To validate this hypothesis, he tried, without success though, to target tumours using inhibitors 56 
of respiration such as selenium derivates [4]. Just two years later, in 1913, Eleanor Van Ness Van Alstyne and 57 
colleagues showed that increased carbohydrate intake resulted in accelerated rat sarcoma growth [5], which was 58 
further confirmed by William Woglom in 1915 [6]. These works supported the notion that tumours use nutrients 59 
such as glucose and oxygen in a different way than normal tissue. Few years later, these findings were 60 
systematically investigated by Otto Warburg. He demonstrated that cancer cells ferment most of their glucose to 61 
lactate even in the presence of normal levels of oxygen, when glucose should be fully oxidised to carbon dioxide 62 
through cellular respiration [7]. After the discovery that respiration is carried out by the mitochondria, Warburg 63 
concluded that all cancers must originate from a mitochondrial dysfunction [8].  64 
After Warburg’s discoveries, the field of cancer metabolism was neglected until the beginning of the 21st 65 
century, when major discoveries and technical advances, including the advent of metabolomics, rekindled the 66 
field. Furthermore, thanks to the availability of large collections of gene expression data from cancer patients, 67 
the metabolic landscape of cancer could be extensively assessed using gene expression of metabolic enzymes. 68 
These bioinformatics analyses showed that both nuclear and mitochondrial DNA-encoded mitochondrial genes 69 
are suppressed in cancer [9–11] and this feature is associated with poor clinical outcome and metastasis [9]. 70 
Noteworthy, not all tumours exhibit mitochondrial impairment and it should be highlighted that the complete 71 
loss of mitochondrial function can be detrimental for cancer cells [12,13]. The role of mitochondrial dysfunction 72 
in cancer was further corroborated by recent sequencing efforts that led to the discovery that mitochondrial 73 
genes, including fumarate hydratase (FH), succinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), 74 
when mutated, cause hereditary and sporadic forms of cancer (reviewed in [14]). Although these discoveries 75 
were made almost twenty years ago, the mechanisms underpinning transformation in these metabolically 76 
impaired tumours are still under intense investigation and could provide unique mechanistic insights into the link 77 
between dysregulated mitochondrial function and transformation. In this review we will focus on the role of FH 78 
loss in cancerous transformation.  79 
 80 
2. Fumarate Hydratase mutations in human diseases 81 
In the human genome the gene encoding FH is located in the chromosome locus 1p43 and encompasses 22229 82 
bases transcribing for 10 exons (NCBI database, NG_012338.1) that give rise to the FH monomer, which 83 
exhibits a “tridomain” structure, with a central domain involved in the interactions with the other monomers, an 84 
N terminal Lyase 1 domain, and a C-terminal Fumarase C domain (Ensembl database, FH-001 85 
ENST00000366560.3) (Fig. 1A). Interestingly, the FH gene encodes for both the cytosolic and the mitochondrial 86 
variant, which differ in the peptide sequence at the N-terminus [15]. Despite the existence of a mitochondrial and 87 
a cytosolic isoform of FH, known as echoforms [16], how these two variants are generated was matter of debate. 88 
Whilst it was initially proposed that these two isoforms are generated by differential mRNA processing [17], 89 
more recent data suggest that they result from an alternative initiation of the transcription [18]. The 90 
homotetrameric mitochondrial FH protein, is part of the tricarboxylic acid (TCA) cycle, where it catalyses the 91 
reversible hydration of fumarate to malate [19] (Fig. 1B).  92 
Mutations of FH have been described in the literature and have been implicated in the pathogenesis of 93 
various diseases. For instance, the homozygous germline loss of FH is the cause of an autosomal recessive 94 





colleagues [20]. Patients with fumaric aciduria display a biallelic loss of FH due to missense and frameshift 96 
mutations or partial deletions, which results mainly in brain abnormalities, developmental delay, and 97 
accumulation of fumarate in the urine [21]. Patients affected by fumaric aciduria rarely survive childhood. 98 
Unfortunately, apart from dietary interventions with unclear efficacy, there are no therapies available for this 99 
disease [22]. 100 
Heterozygous germline mutations of FH predispose to Hereditary Leiomyomatosis and Renal Cell Cancer 101 
(HLRCC), a cancer syndrome characterised by cutaneous, uterine leiomyomas, and renal cancer [23]. HLRCC 102 
patients harbour one mutant FH allele and the loss of the wild type allele by loss of heterozygosity leads to 103 
benign tumours of the skin and uterus, and papillary type II renal cell carcinomas (RCC), one of the most 104 
aggressive forms of renal cancer characterised by early metastasis and a poor clinical outcome [24]. So far, no 105 
correlation between the site of mutations and clinical outcome in patients has been established, indicating that 106 
the loss of FH activity, rather than any neomorphic functions of the mutant protein, is responsible for cellular 107 
transformation [25]. Interestingly, the sporadic loss of FH has been reported in other tumour types such as 108 
pheochromocytomas, paragangliomas [26,27], adrenocortical carcinoma [28], neuroblastomas [28,29], glioma, 109 
ependymoma, osteosarcoma, and Erwing’s sarcoma [28] (Fig. 1C). Consistent with a broader role of FH in 110 
tumorigenesis, its transcriptional downregulation was found in sporadic clear cell carcinomas [30] and in 111 
colorectal cancer [31], and additional evidence suggests the involvement of FH mutations in breast, bladder, and 112 
testicular cancers [32]. These findings hint at a key role of FH loss in human cancers. Yet, how its loss promotes 113 
tumorigenesis is still debated. The molecular alterations caused by FH loss that are implicated in tumorigenesis 114 
will be discussed in the next paragraphs.  115 
 116 
3. FH loss induces a multi-layer cellular reprogramming that leads to 117 
transformation 118 
3.1. Metabolic rewiring in FH-deficient cells 119 
The TCA cycle is a set of metabolic reactions within the mitochondria that represents the final converging route 120 
for the oxidation of lipids, carbohydrates, and amino acids [33]. Consequently, TCA cycle enzymes are essential 121 
for cell growth and survival, and it came as a surprise that FH loss could not only be tolerated by cells, but that it 122 
could also cause cancer. Therefore, it was argued that FH-deficient cells must respond to this mitochondrial 123 
impairment by compensatory metabolic changes. We and others have extensively investigated these metabolic 124 
changes, which are summarised in Fig. 2. First, as often observed in mitochondrial diseases, FH-deficient cells 125 
increase their glycolytic rates and instead of oxidising glucose in the mitochondria they shunt it into lactate 126 
production [34] and other glycolytic branches, including the pentose phosphate pathway (PPP) [35]. 127 
Interestingly, as will be detailed in section 3.2.2, this glycolytic shift is supported by a transcriptional 128 
reprogramming of glycolytic enzymes and the inhibition of pyruvate dehydrogenase (PDH), which in turn blocks 129 
the entry of glucose into the mitochondria [36] (Fig. 2 and Fig. 4). To fuel this truncated TCA cycle when 130 
glucose entry in the mitochondria is reduced, glucose is replaced by glutamine as the main source of carbons 131 
[34] (Fig. 2). Glutamine fuels part of the TCA cycle supplying α-ketoglutarate (αKG) allowing through αKG 132 
dehydrogenase the generation of NADH, used by oxidative phosphorylation (OXPHOS) for ATP generation and 133 
for the maintenance of mitochondrial membrane potential [34]. The latter is necessary for a variety of 134 
mitochondrial processes that needs to be preserved for cell survival, including protein translocation, ion 135 
exchange and metabolite transport, and it also regulates mitochondrial quality control, cell death, and 136 
mitochondrial retrograde signalling [37]. To maintain this linear set of reactions without reaching saturation due 137 
to FH loss, some glutamine-derived carbons are diverted towards the haem biosynthesis and degradation 138 
pathway, which is essential for the survival of FH-deficient cells [34] (Fig. 2). Moreover, in human FH-mutant 139 
cells, UOK262 cells, glutamine is converted to αKG and eventually to citrate for lipid biosynthesis via the 140 
reversal of IDH and aconitase (ACO) in a process called reductive carboxylation [38] (Fig. 2). Of note, this 141 
process uses both cytosolic and mitochondrial NADP+-dependent IDH isoforms (IDH1 and 2, respectively) and 142 
provides key TCA cycle intermediates normally generated from glucose, such as citrate and isocitrate, and also 143 





is controversial since it was observed in human FH-deficient cells, but not in mouse Fh1-deficient epithelial 145 
cells[34] or fibroblasts [40]. This apparent inconsistency between the mouse and human models could be 146 
explained by the fact that the human FH-deficient cells accumulate lower levels of fumarate than the mouse 147 
counterparts [41]. As a key component of the set of reactions of reductive carboxylation, the mitochondrial ACO 148 
(ACO2), is inactivated by fumarate [40] (more details in section 3.2.1), it is possible that the lower fumarate 149 
levels observed in UOK262 could spare ACO2 from fumarate-driven inactivation, preserving the ability to 150 
perform reductive carboxylation in these cells. Given that reductive carboxylation offers important bioenergetics 151 
and biosynthetic advantages for tumour growth in cells with defective mitochondria [38] it is also possible that 152 
FH-deficient clones harbouring lower levels of fumarate and preserved ACO2 function are selected during 153 
tumour progression.   154 
Fumarate accumulates to millimolar levels in FH-deficient cells[41] and it is the most striking 155 
biochemical feature associated to FH loss [34,41]. At this concentration, fumarate could permeate multiple 156 
subcellular compartments including mitochondria, cytosol, and nuclei [42–44] as well as the extracellular 157 
microenvironment [36]. High fumarate levels could alter the balance of multiple enzymatic reactions in which 158 
this metabolite is directly involved as either substrate or product. For instance, it was shown that fumarate 159 
accumulation impacts the conversion of succinate to fumarate by SDH in the TCA cycle, reducing SDH-160 
dependent mitochondrial respiration [45] (Fig. 2). Other examples of pathways dysregulated by fumarate 161 
accumulation are the urea cycle [43] and the purine nucleotide cycle (PNC) [46] (Fig. 2). Within the urea cycle, 162 
argininosuccinate produced from citrulline and aspartate is normally converted to arginine and fumarate by the 163 
enzyme argininosuccinate lyase (ASL) [41]. The accumulation of fumarate can reverse this reaction, driving the 164 
synthesis of argininosuccinate from exogenous arginine and fumarate [41] (Fig. 2). In turn, FH-deficient cells 165 
require arginine to buffer fumarate and its depletion is lethal for FH-deficient cells [41,43]. Another metabolic 166 
pathway predicted to be affected by fumarate accumulation is the PNC, whereby the increase in fumarate may 167 
cause the reversal of adenylosuccinate lyase (ADSL) to form adenylosuccinate (Fig. 2). However, besides the 168 
observation of an accumulation of adenylosuccinate in mouse Fh1-deficient cells [47], there is no formal 169 
experimental evidence that ADSL reversal occurs in FH-deficient cells. Overall, these results show that the loss 170 
of FH leads to profound metabolic changes that are required to compensate for the truncation of the TCA cycle 171 
and for the aberrant accumulation of fumarate. Failure to activate these metabolic scape valves has been shown 172 
to be detrimental for FH deficient cells [48], arguing that these changes are a first essential step for 173 
tumorigenesis.  174 
 175 
3.2. Pro-oncogenic signalling activated by FH loss 176 
3.2.1. Oncogenic signalling via fumarate-dependent succination  177 
Besides the above-described metabolic reprogramming (section 3.1.), whose contribution to the transformation 178 
process is still unclear, FH loss and fumarate accumulation elicit a plethora of pro-oncogenic signals that can 179 
directly contribute to transformation. The first type of oncogenic signalling activated by fumarate is related to its 180 
chemical structure. Fumarate is a mild electrophilic molecule due to the low electron density in its double bond 181 
caused by the conjugation to two carboxylic acid residues [49] (Insert in Fig. 3). At acidic pH conditions typical 182 
of cancer cells [50], fumarate can react with nucleophilic residues such as thiol groups from cysteine residues 183 
exposed at the surface of proteins, generating a stable thioether known as S-(2-succino) cysteine (2SC) [51]. This 184 
post-translational modification, succination [52], is not only irreversible and resistant to acidic hydrolysis, but it 185 
manifests only at pathological levels of fumarate, making it an excellent diagnostic marker of FH-deficiency in 186 
cancer patients [53]. So far, various proteins have been identified as targets of succination including the Kelch-187 
like ECH-associated protein1 (KEAP1) [54,55], iron regulatory protein 2 (IRP2) [56], the iron-sulfur-cluster (Fe-188 
S cluster) biogenesis family of proteins [45], aconitase (ACO2) [40], glutathione (GSH) [57,58] and SWI/SNF 189 
Related, Matrix Associated, Actin Dependent Regulator Of Chromatin Subfamily C Member 1 (SMARCC1)[50] 190 
(Fig. 3). We will briefly describe them within this section below.  191 
The succination of KEAP1 was one of the first post-translational modifications triggered by fumarate to 192 
be identified [54,55]. Under physiological conditions, KEAP1, a E3 ubiquitin ligase, binds Nuclear Factor, 193 





that belongs to the family of basic leucine zippers (bZIP) activated in response to oxidative stress [59]. In FH-195 
deficient cells, the succination and subsequent inactivation of KEAP1 prevents the degradation of NRF2, which 196 
in turn is allowed to translocate in the nucleus, mounting a potent antioxidant response mediated by genes such 197 
as haem oxygenase 1 (HMOX), NAD(P)H dehydrogenase quinone 1 (NQO1), and glutamate-cysteine ligase 198 
catalytic subunit (GCLC) [55,60]. The role of NRF2 in tumorigenesis is debated and context-dependent. On one 199 
hand, NRF2 activation can prevent cellular transformation triggered by specific carcinogens such as 200 
benzo[α]pyrene and aflatoxin B1 by facilitating their detoxification (REF). On the other hand, the antioxidant 201 
response activated by NRF2 elicited by oncogenes such as Kras, Braf and Myc can prevent the damages caused 202 
by oxidative stress, and therefore favour tumour survival [61]. The contribution of NRF2 to cellular 203 
transformation in FH-deficient cells is still unclear but we will discuss its potential role later in the section 4 204 
Another target of succination is the iron regulatory protein 2 (IRP2) [56] (Fig. 3), a protein that normally 205 
suppresses the translation of ferritin, a key player in iron homeostasis [62]. When inactivated by succination, 206 
IRP2 allows the expression of ferritin, leading to the depletion of freely available iron [56] with important 207 
consequences for the Fe-S cluster formation. The depletion of Fe-S clusters may indirectly induce a 208 
mitochondrial dysfunction through the impairment of RC and other mitochondrial proteins, potentially leading  209 
to transformation. Moreover, the upregulation of ferritin was also shown to activate forkhead box protein M1 210 
(FOXM1), promoting cell growth [56].  211 
Fe-S cluster assembly family of proteins is another target of succination (Fig. 3). These proteins include 212 
Fe-S cluster scaffold (NFU1), Fe-S cluster assembly enzyme (ISCU) 1 and 2, and BolA family member (BOLA) 213 
1 and 3 [45]. This family of proteins is required for the correct synthesis and integration of Fe-S cluster in 214 
various proteins, including electron transport chain complexes I, II, III, and ACO2 [45]. Through the impairment 215 
of the assembly of Fe-S clusters, fumarate indirectly reduces the activity of the RC complex I, which together 216 
with the above-described inhibition of complex II (Section 3.1.) , reduces the overall activity of the RC [45].  217 
ACO2 was also found to be succinated by fumarate on three different cysteine residues (C385, C448, 218 
and C451) in Fh1-/- MEFs [40]. As a consequence of succination, ACO2 activity is impaired and this inactivation 219 
may prevent Fh1-deficient MEFs to use glutamine for citrate formation through reductive carboxylation[40].  220 
Succination can also target the tripeptide glutathione (GSH) [57,63]By depleting this important 221 
antioxidant molecule, FH-deficient cells experience an increased oxidative stress, which is balanced by an 222 
increase in GSH biosynthesis [57].  223 
Finally, very recent work showed that SMARCC1, a member of the SWI–SNF tumour-suppressor 224 
complex, is succinated by fumarate on cysteine residue 520 [64]. Of note, this complex functions as a ATP-225 
dependent chromatin remodelling factor and regulates the structure of the nucleosome [64]. Intriguingly, the 226 
cysteine sensitive to fumarate is contained within the SWIRM domain of the protein, usually mutated in other 227 
cancer types and also responsible for interaction with other downstream proteins such as SWI/SNF Related, 228 
Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 5 (SNF5) [50]. As a 229 
consequence of succination, the interaction between SMARCC1 and SNF5 is weakened and HLRCC cells shows 230 
similar transcriptional profile compared to SNF5-deficent cell s[50].  231 
Together, these pieces of evidence show that upon FH loss the accumulation of fumarate can trigger a 232 
broad range of signalling cascades via succination, and the role of these cascades in tumorigenesis of HLRCC is 233 
only now beginning to be understood.  234 
3.2.2. Oncogenic signalling mediated by fumarate via aKGDDs inhibition 235 
Another target of fumarate accumulation is the superfamily of αKG-dependent-dioxygenases (aKGDDs), 236 
proteins involved in multiple biological processes, including protein hydroxylation, DNA and histone 237 
demethylation, and RNA modifications (Fig. 4). These enzymes use αKG and oxygen as substrates, iron and 238 
vitamin C as cofactors, and produce succinate and carbon dioxide [65]. Fumarate acts as a competitive inhibitor 239 
of these enzymes, with important biological consequences, which will be described in this section below.  240 
The human genome encodes for three aKGDDs prolyl-hydroxylases (PHD1-3), all of which use 241 
molecular oxygen to generate an hydroxyl group on proline residues of proteins [66]. Under normoxic 242 





Pro 402 and Pro 564 [66], leading to their proteasomal degradation [67,68]. In the early 2000s it was shown that 244 
the competitive inhibition of PHDs by fumarate can lead to the stabilisation of HIF1-α/HIF2-α [69] even at 245 
normal oxygen levels, a phenomenon known as pseudohypoxia [32]. FH-deficient cells display the activation of 246 
typical HIF targets that are involved in angiogenesis, growth, and metabolism [70,71] (Fig. 4). Among the target 247 
genes of HIFs there are several metabolic enzymes including the glucose transporter 1 (GLUT1) [69], which 248 
increases glucose uptake, pyruvate dehydrogenase kinases (PDKs) [72,73], which inhibits pyruvate 249 
dehydrogenase (PDH), and lactate dehydrogenase A (LDH-A) [74] . Together, these genes switch off 250 
mitochondrial oxidative metabolism and redirect glycolytic pyruvate towards lactate production, as described in 251 
section 3.1. and in Fig. 2. Furthermore, HIFs activate vascular endothelial growth factor (VEGF), which has 252 
important implication for tumour invasiveness and cross activation of other oncogenic signalling mediated by 253 
platelet derived growth factor (PDGF) [69,75,76]. Despite these lines of evidence pointing at an important role 254 
of HIFs in HLRCC biology, the role of these transcription factors in tumorigenesis is still debated. For instance, 255 
it was shown the genetic deletion of both Hif1and Hif2 does not prevent the formation of premalignant lesions in 256 
Fh1-deficient animals, suggesting that at least in this model, HIF proteins are dispensable for tumorigenesis [54]. 257 
Within the nucleus of a cell, chromatin structure and function are finely regulated by chemical changes 258 
of DNA and histones catalysed by aKGDD DNA and histone demethylases. DNA demethylation is catalysed by 259 
a family of proteins known as Ten-Eleven Translocation (TETs) proteins [77], whilst histone demethylation is 260 
carried out by Lysine demethylases (KDMs) [78]. By altering the activity of these enzymes, fumarate can affect 261 
chromatin organisation, eventually perturbing gene expression. 262 
TETs are a family of three proteins that catalyse the demethylation of cytosine residues on DNA [77], a 263 
process linked with the activation of gene expression [79]. Therefore, by blocking TET-dependent DNA 264 
demethylation, fumarate could suppress the expression of several genes. For instance, FH loss is associated with 265 
the hypermethylation and suppression of the tumour suppressor cyclin dependent kinase inhibitor 2A (CDKN2A) 266 
 [80,81] (Fig. 4), which encodes for p16, an inducer of senescence [82]. Fumarate can also cause the 267 
hypermethylation and suppression of a family of antimetastatic miRNAs, MIR200 [83], known inhibitors of the 268 
transcription factors Zinc Finger E-Box Binding Homeobox 1/2 (ZEB1 and ZEB2) and Snail homolog 2 269 
(SNAI2), leading to an epithelial-to-mesenchymal transition (EMT), a process known to promote metastatic 270 
dissemination [84,85]. Interestingly, the link between the induction of EMT and FH loss was further strengthen 271 
by the finding that the chromatin remodelling factor lymphoid-specific helicase (LSH) triggers an EMT by 272 
suppressing FH in nasopharyngeal carcinoma [86].  273 
Another important family of aKGDDs involved in epigenetic reprogramming is the Jumonji-containg 274 
histone lysine demethylases (JmjC-KDMs) [87] (Fig. 4). These enzymes remove the methyl group from lysine 275 
residues of histones, which are known to  regulate chromatin accessibility and gene expression [78,87]. Only 276 
recently it has been shown that fumarate accumulation, through inhibition of JmjC-KDMs, increases the global 277 
levels of methylation of lysine 4, 27, and 79 of histone 3 (H3K4, H3K27, and H3K79, respectively) [88]. These 278 
histone marks are associated to activation and repression of gene transcription, respectively. However, the 279 
biological consequences of a fumarate-dependent inhibition of histone demethylation are still unclear. 280 
A less characterised aKGDD target of fumarate is the fat mass and obesity associated (FTO) [89] (Fig. 4). 281 
FTO was originally characterised as a protein that catalyses the demethylation of 3-methylthymine (3mT) in 282 
single stranded DNA of mice [89]. However, only few years ago it was clarified that its main activity is the 283 
demethylation of N6-methyladenosine of RNA [90,91]. Even though it was shown that in vitro FTO is sensitive 284 
to fumarate levels as the other aKDDG [89], the role of FTO inhibition within FH-dependent tumorigenesis is 285 
still largely unexplored and there is no evidence that FTO is inhibited in FH-deficient tumours. 286 
3.3. Other molecular cascades affected by FH loss 287 
Beyond the inhibition of aKGDDs and the targeting of proteins via succination, other molecular pathways that 288 
are potentially involved in the tumorigenic process are differentially modulated in FH-deficient cells. For 289 
instance, it has been shown that FH loss alters the activation of the AMP-activated protein kinase (AMPK) [92], 290 
the mammalian target of rapamycin (mTOR)[92] and Abelson murine leukaemia viral oncogene homolog 1 291 





and DNA-damage response (DDR) pathway [96,97]. The role of these cascades in FH-deficient cells will be 293 
briefly described in this section below (Fig. 5). 294 
AMPK is a heterotrimeric kinase activated by alterations in the energetic balance [98]. The protein 295 
complex consists of two catalytic subunits (α1 and α2) and two regulatory subunits (β and γ) [99]. AMPK 296 
activation is tightly controlled by both ADP:ATP and AMP:ATP ratios, acting therefore as sensor of the 297 
bioenergetic status of the cells [100]. When cells experience energy stress and AMP levels raise, AMPK blocks 298 
anabolic processes and activates catabolism, including fatty acid oxidation and autophagy [101]. In HLRCC 299 
tumours, AMPK activity and its phosphorylation are reduced compared to normal kidney tissue [92] (Fig. 5). 300 
Even though it is still not clear which mechanisms lead to suppression of AMPK in FH-deficient tumours, this 301 
cascades increases the activity of acetyl CoA carboxylase (ACC), one of the main regulatory enzymes of the de 302 
novo lipid biosynthesis [92], and causes the repression of divalent metal transporter 1 (DMT1), reducing freely 303 
available iron [92]. More importantly, it was shown that AMPK inhibition may cross-activate mTOR signalling 304 
in FH-deficient tumours [92]. Consistently, S6 ribosomal protein Kinase (S6K), a downstream effector of 305 
mTOR, is phosphorylated in FH-deficient cells, and increases the global protein biosynthesis [92]. Additionally, 306 
Linehan and co-workers showed that also ABL-1 activation via the oxidation of the protein-tyrosine phosphatase 307 
N12 (PTPN12) converge to mTOR signalling in FH-deficient cells [93]. Intriguingly, the connection between 308 
FH and mTOR appears bidirectional since the chronic activation of mTOR complex1 (mTORC1) through the 309 
deletion of Tuberous Sclerosis complex1/2 (Tsc1/2) represses Fh1 thus contributing to a fumarate-dependent 310 
transformation in RCC mouse model [102].  311 
Another important regulator of cell signalling is the cyclic nucleotide cAMP [103] (Fig. 5). cAMP 312 
signalling is often increased in cancer through different molecular strategies that depends on the tumour type 313 
[103]. cAMP levels are tightly controlled by two different types of enzymes, adenylate cyclases, which are 314 
responsible for the generation of cAMP from ATP, and phosphodiesterases, which convert cAMP back to AMP 315 
[103]. Both enzymes respond to other signalling cascades including calcium signalling, calmodulin, calcineurin, 316 
and receptor tyrosine kinases [103]. A synthetic lethal screenings performed on FH-deficient cells revealed that 317 
multiple adenylate cyclases are essential for FH-deficient cells [95]. The higher turnover of cAMP observed 318 
upon FH loss suggests that other downstream targets of cAMP, such as cAMP-activated protein kinases (PKA) 319 
may play a role in FH-dependent tumorigenesis [95]; however this aspect of FH biology is largely unexplored.  320 
Another important biological process controlled by FH and fumarate levels is DDR (Fig. 5). DDR is a 321 
complex and articulated process that follows DNA damage [104]. Its role has been widely studied in cancer 322 
research mainly in connection with genomic instability and radiotherapy [104]. Few recent works shed light on a 323 
new function of FH and fumarate accumulation in DDR. It was shown that upon DNA damage, FH translocates 324 
in the nucleus at the sites of damage, where it produces a local pool of fumarate that causes the inhibition of 325 
histone H3K36 demethylation, an important step in DDR, and the binding of pro-non homologous end joining 326 
(pro-NEHJ) proteins [105]. Secondly, the accumulation of fumarate was shown to correlate with increased 327 
endogenous DNA damage, inhibition of homologous recombination repair, and increased sensitivity towards 328 
poly-ADP ribose polymerase inhibitors (PARP inhibitors) [106]. Finally, FH-deficient cells displayed not only a 329 
marked resistance to DNA damage caused by ionising radiation but also an early mitotic entry even in a 330 
condition of unrepaired damage [96]. 331 
4. A possible paradigm of tumorigenesis in HLRCC 332 
In the previous paragraph of this review we provided compelling evidence that upon FH loss cells orchestrate a 333 
multifaceted reprogramming that includes pro-survival metabolic adaptations and the activation of oncogenic 334 
cascades. However, the specific contribution of these signalling cascades toward cellular transformation is not 335 
fully understood. Based on our current understanding, we postulate that tumorigenesis driven by FH loss occurs 336 
via a series of steps over time, largely divided into a “metabolic adaptation” phase, and a subsequent activation 337 
of oncogenic signalling cascades mediated by fumarate (Fig. 6). First, upon FH loss, cells must adapt to the 338 
profound dysfunction generated by the truncation of the TCA cycle, engaging in a series of compensatory 339 
metabolic adaptations, including the switch towards glycolysis, and activation of glutamine oxidation. Under 340 





fumarate, cells exploit a series of strategies to buffer this metabolite, including protein succination and the 342 
reversal of biochemical pathways that normally produce fumarate. At this stage, FH-deficient cells might 343 
experience a profound oxidative stress caused by the disruption of mitochondrial function and depletion of GSH 344 
that lead to senescence. The fine tuning of an antioxidant response is likely important for the survival and growth 345 
of FH-deficient tumours at this stage. It is tempting to speculate that the activation of antioxidant programmes 346 
such as those triggered by NRF2 via succination of KEAP1 are not just important to escape cell death triggered 347 
by excessive oxidative stress but could also contribute to avoid senescence, paving the way to transformation in 348 
FH-deficient cells. Yet, it should be noted that the activation of NRF2 can be tumour suppressive, by allowing 349 
detoxification from excessive fumarate with increased GSH biosynthesis [57] and activating HMOX1 [34]. 350 
Additionally, the epigenetic suppression of p16 could be another important step to overcome senescence in FH-351 
deficient cells. In parallel, fumarate accumulation causes the inhibition of multiple aKGDDs. Of note, 352 
PHDs/TETs/KDMS inhibition appears to occur via the combination of fumarate accumulation and the parallel 353 
decrease in freely available iron, a key cofactor for these enzymes [107]. The inhibition of aKGDDs orchestrates 354 
a complex transcriptional and epigenetic rewiring in FH-mutant tumours. Of note, the epigenetic silencing of p16 355 
and activation of EMT can both help to evade senescence and promote cell migration and invasion. Whether 356 
these events are involved in the early phases of transformation or if they emerge at a later stage of tumour 357 
progression and are implicated in tumour metastasis is still an open question in the field. Understanding this 358 
question will be key to elucidate which of the pathways triggered by fumarate should be targeted to prevent 359 
tumour formation and/or progression. 360 
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Figure Legends 731 
Figure 1. Fumarate Hydratase and cancer. A) schematic representation of Fumarate Hydratase (FH) gene and 732 
protein. B) Depiction of the chemical reaction catalysed by FH, which converts fumarate to malate. C) 733 
Representation of the various tissue where the sporadic or hereditary loss of FH leads to cancer. HLRCC: 734 
hereditary Leiomyomatosis and renal cell carcinoma. 735 
Figure 2. Metabolic rewiring in FH-deficient cells. The biallelic loss of FH leads to the truncation of 736 
the TCA cycle and the subsequent accumulation of fumarate (highlighted in orange). The combined disruption of 737 
the TCA cycle and the inhibition of Succinate Dehydrogenase (also known as Complex II of the respiratory 738 
chain) by fumarate significantly reduce mitochondrial respiration. To compensate for the loss of mitochondrial 739 
function, FH-deficient cells engage in a complex biochemical rewiring. First, FH-deficient cells shift towards 740 
aerobic glycolysis reducing the oxidation of glucose in the mitochondria (lilac arrows). Part of carbons from 741 
glucose are diverted toward the pentose phosphate pathway (PPP) to maintain redox homeostasis (lilac arrow). 742 
Furthermore, to maintain the remaining TCA cycle activity and sufficient NADH generation, FH-deficient cells 743 
increase glutamine oxidation (red arrows). Glutamine-derived carbons are further metabolized to fumarate and, 744 
via the haem pathway, to biliverdin and bilirubin, which is secreted in the medium, or are used to generate 745 
lipogenic acetyl-CoA via reductive carboxylation (yellow arrows). FH-deficient cells also activate multiple 746 
strategies to buffer the potentially toxic accumulation of fumarate. For instance, fumarate permeates the various 747 
intracellular compartments, including the nucleus, and can be released in the extracellular milieu. Fumarate 748 
accumulation leads to the aberrant production of argininosuccinate via the reversal of the urea cycle enzyme 749 
argininosuccinate lyase (ASL) (turquoise arrows). Of note, FH-deficient cells require constant supply of 750 
exogenous arginine to maintain this buffering system active and die when arginine is depleted. Finally, fumarate 751 
leads to the accumulation of adenylosuccinate, likely via the reversal of adenylosuccinate lyase (ADSL) within 752 
the purine nucleotide cycle (PNC). AMP= adenosine monophosphate; CI-V=Electron transport chain Complex I-753 
V; PDH: pyruvate dehydrogenase; GLUT1=glucose transporter 1; HMOX1=haem oxygenase 1; IMP= inosine 754 
monophosphate. 755 
Figure 3. Targets of succination in FH-deficient cells. Fumarate, accumulated upon FH loss, leads to 756 
a post translational modification of cysteine residues of a variety of proteins (violet hexagons) called succination. 757 
The chemical reaction between fumarate and reactive thiol residues of proteins is in depicted in the insert. 758 
Succination of KEAP1 causes the stabilisation and activation of the NRF2-mediated anti-oxidant response. One 759 
of the targets of NRF2 is Haem Oxygenase 1 (HMOX1), which is required for the haem biosynthesis and 760 
degradation pathway, an essential pathway for the survival of FH-deficient cells. Succination of Iron Responsive 761 
Element Binding Protein 2 (IRP2) inhibits the repressive function of this protein on the translation of ferritin. 762 
The subsequent increase in ferritin causes a drop in free intracellular iron. In parallel, ferritin promotes the 763 
expression of Forkhead box protein M1 (FOXM1), a pro-mitotic protein that supports cell growth. Succination 764 
of the Fe-S cluster proteins Nfu1, Bola and Iscu impairs the Fe-S clusters assembly required by the electron 765 
transport chain complex I, contributing to defects in mitochondrial respiration. The reduction of iron and the 766 
succination of key cysteine residues in its catalytic core also inactivates the TCA cycle enzyme Aconitase 2 767 
(ACO2). In the nucleus, the succination of SWI/SNF complex protein SMARCC1 inactivates this complex, 768 
affecting gene expression and chromatin remodelling. Finally, GSH succination causes the depletion of 769 
glutathione (GSH) stores, increasing oxidative stress, and triggering senescence in primary FH-deficient cells. 770 
CI-V=electron transport chain complex I-V; KEAP1=Kelch Like ECH Associated Protein 1; Bola1-3=BolA771 
Family Member 1-3ISCU= Iron-Sulfur Cluster Assembly Enzyme; NFU1=NFU1 Iron-Sulfur Cluster Scaffold; 772 
NRF2=Nuclear Factor, Erythroid 2 Like 2; SMARCC1=SWI/SNF Related, Matrix Associated, Actin Dependent 773 
Regulator Of Chromatin Subfamily C Member 1. GCLC: glutamate-cysteine ligase; NQO1: NADH quinone 774 
oxidase 1. 775 
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Figure 4. Oncogenic signalling mediated via aKGDDs inhibition in FH-deficient cells. Upon FH loss, 776 
fumarate accumulation inhibits the activity of various aKGDDs (grey hexagons). For instance, fumarate inhibits 777 
prolyl hydroxylases (PHDs), causing the stabilisation of the alpha subunit of a family of hypoxia inducible 778 
factors (HIFs) even in the presence of normal oxygen levels. The transcriptional response elicited by HIFs 779 
promotes angiogenesis, tumour growth, and aerobic glycolysis via increased expression of the glucose 780 
transporter GLUT1, and lactate dehydrogenase (LDHA). Furthermore, HIF triggers the expression of pyruvate 781 
dehydrogenase kinase 1 (PDK1), which phosphorylates and inhibits pyruvate dehydrogenase complex (PDH), a 782 
gatekeeper of glucose-derived pyruvate in the mitochondria. In the nucleus, fumarate accumulation induces a 783 
profound epigenetic reprogramming due to the inhibition of both DNA and histone demethylases (TETs and 784 
KDMs respectively). In particular, the inhibition of the demethylation of miR200 was shown to trigger an 785 
epithelial-to-mesenchymal transition (EMT) in FH-deficient cells. Finally, the inhibition of the RNA 786 
demethylase FTO by fumarate accumulation is predicted to increase RNA methylation. A=adenosine; FTO=Fat 787 
Mass and Obesity-Associated Protein; H3K4-me2= dimethylated arginine 4 in Histone H3; H3K4-3me= 788 
trimethylated H3K4; HIFα= hypoxia inducible factor subunit α; HIF-OH= hydroxylated; KDMs=Lysine 789 
Demethylases; miR200-C= unmethylated microRNA 200 gene; miR200-mC= methylated microRNA 200 gene; 790 
m6A=N6 methyl-adenosine; PDGF= Platelet Derived Growth Factor; TETs= Ten-Eleven Translocation Gene 791 
Proteins; VEGF=Vascular Endothelial Growth Factor. 792 
Figure 5: Other molecular cascades affected by FH loss. Upon FH loss, distinct signalling nodes have been 793 
found dysregulated (grey hexagons), and to activate key downstream proteins (green rectangles). For instance, 794 
the oxidation and inactivation of the protein phosphatase PTPN12 activates the kinase ABL1, which in turn 795 
activates mTOR and NRF2. The activation of mTOR is key to increase general protein synthesis via the 796 
phosphorylation of S6K. In parallel, AMPK is suppressed in FH-deficient cells, further activating mTOR and 797 
Acetyl CoA carboxylase (ACC), thus promoting lipid biosynthesis. The inactivation of AMPK also leads to the 798 
p53-dependent suppression of the iron transporter DMT1, decreasing iron uptake and reducing of the free iron 799 
pool. FH deficient cells were shown to depend on the activity of a set of Adenylate Cyclases (AC), which 800 
increase the total pool of cyclic AMP (cAMP) in the cells. Finally, the accumulation of fumarate increases 801 
resistance to DNA damage by ionising radiations (IR) and favours non-homologous end-joining upon DNA 802 
damage, via inhibition of KDM6, a key histone demethylase implicated in chromatin unfolding for DNA repair. 803 
ABL1= Abelson murine leukaemia viral oncogene homolog 1; DMT1= Divalent metal transporter 1; H3K36-804 
me2= dimethylated arginine 36 on Histone H3; H3K36-3me= trimethylated H3K36; KDMs=Lysine 805 
Demethylases; mTOR= mechanistic target of rapamycin; p53= tumour suppressor protein 53; AMPK= AMP-806 
activated protein kinase; PTPN12=Tyrosine-protein phosphatase non-receptor type 12; S6K= S6 ribosomal 807 
protein kinase. 808 
Figure 6: Tumorigenesis in FH-deficient cancer. We hypothesise that tumorigenesis in FH-deficient cells is a 809 
multi-step process. First, upon FH loss, cells undergo a series of biochemical adaptations in order to compensate 810 
for the loss of FH and for the truncation of the TCA cycle. These compensatory changes support the elevation of 811 
intracellular fumarate, which in turn can lead to senescence due, at least in part, to oxidative stress. In parallel, 812 
fumarate can induce epigenetic changes, such as hypermethylation of p16, that can enable the bypass of 813 
senescence. The activation of additional oncogenic cascades, including those orchestrated by NRF2, ABL1, and 814 
HIF contribute to cellular transformation. 815 
816 
817 






